Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Dr. Vania Hungria presents the Phase 3 DREAMM-7 trial results, demonstrating that belantamab mafodotin, bortezomib, and dexamethasone (BVd) achieved a statistically significant and clinically meaningful overall survival benefit over daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma, with deep, durable responses and manageable safety outcomes.

Laura J Chambers, DO

Latest:

Dr Chambers on the Importance of Patient Counseling in Ovarian Cancer

Laura J. Chambers, DO, discusses the importance of treatment counseling for patients with ovarian cancer considering PARP inhibitor therapy.

Sujith Samarasinghe, MD

Latest:

Dr Samarasinghe on the Feasibility of First-Line Blinatumomab in Down Syndrome B-ALL

Sujith Samarasinghe, MD, discusses key results from the phase 2 ALLTOGETHER 1 DS trial in Down Syndrome B-cell acute lymphoblastic leukemia.

Phillip Dennis, Vice President, Lung Cancer and CEACAM Global Project Head, Sanofi

Latest:

Responding to Resistance in Lung Cancer

Mattia Garutti, MD

Latest:

Dr. Garutti on the Potential Shift to Neoadjuvant Therapy in Melanoma

Mattia Garutti, MD, discusses the potential shift to neoadjuvant therapy in melanoma.

Daniel Pollyea, MD, MS

Latest:

Review of the SELECT-AML-1 Trial and the Future of Newly Diagnosed AML

Daniel Pollyea, MD, MS, reviews the ongoing SELECT-AML-1 trial and comments on novel therapies and biomarkers in patients with newly diagnosed unfit AML.

Arun Azad, PhD

Latest:

Dr. Azad on the Significance of the PROfound Trial in mCRPC

Arun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.

Caroline Farrington, PhD

Latest:

Dr. Farrington on the Importance of Genetic Testing in CRC

Caroline Farrington, PhD, discusses the importance of genetic testing in colorectal cancer.

Shahab Babakoohi, MD

Latest:

Metastasis Patterns of Basal Cell Carcinoma

A look at how common metastatic basal cell carcinoma is in clinical practice and when to consider frontline immunotherapy.

Seema Nagpal, MD

Latest:

Dr Nagpal on the FDA Approval of Vorasidenib for Grade 2 Astrocytoma or Oligodendroglioma

Seema Nagpal, MD, discusses the FDA approval of vorasidenib for patients with astrocytoma or oligodendroglioma harboring IDH1 or IDH2 mutations.